View Post

Final Results of the KRISTINE Trial in HER2-Positive Breast Cance

In Clinical Trials by Barbara Jacoby

By: Dave Levitan From: Treatment for HER2-positive breast cancer with trastuzumab emtansine (T-DM1) plus pertuzumab yielded a higher risk of event-free survival (EFS) events compared with trastuzumab, pertuzumab, and chemotherapy, according to a phase III trial. There was a similar risk of invasive disease–free survival (IDFS) events, though, suggesting that chemotherapy may be unnecessary in some patients. The standard …